PharmaCyte Biotech Appoints Dr. Matthias Löhr to Board of Directors
April 05 2022 - 9:00AM
Business Wire
PharmaCyte Biotech, Inc. (NASDAQ: PMCB), a biotechnology company
focused on developing cellular therapies for cancer and diabetes
using its signature live-cell encapsulation technology,
Cell-in-a-Box®, announced today the appointment of Dr. Matthias
L�hr to PharmaCyte’s Board of Directors.
PharmaCyte’s Chief Executive Officer, Kenneth L. Waggoner,
stated, “PharmaCyte is extremely pleased that Dr. L�hr has joined
our Board of Directors. There is no one who could be more
qualified. His life’s work and passion are specifically in the
areas of the treatments that PharmaCyte is developing. He has held
dozens of trusted leadership roles in learned societies, cancer
research centers, universities, and governmental agencies. He knows
all aspects of our technology and is experienced with it in a
clinical setting. The entire PharmaCyte team looks forward to Dr.
L�hr making our company even stronger as we move into a bright
future with the Cell-in-a-Box technology®.”
Commenting on his appointment, Dr. L�hr said, “It is with great
pleasure that I join PharmaCyte's Board of Directors. With the
company being on the precipice of an FDA clinical trial in locally
advanced, inoperable pancreatic cancer, I can think of no better
opportunity for me to be involved with PharmaCyte’s future
successes. PharmaCyte's pipeline of developing treatments for
cancer and diabetes directly addresses the hard-to-treat diseases
that I have been so passionately involved in over my career. It is
my belief that there is real hope on the horizon for those patients
suffering from these tragic diseases, and I am honored to be a part
of it all."
Dr. Matthias L�hr is Professor of Gastroenterology and
Hepatology at the famed Karolinska Institute in Stockholm, Sweden,
and leads the Pancreatic Team at Karolinska University Hospital. He
has served as Professor of Molecular Gastroenterology at the
University of Heidelberg with a same-named Unit at the German
Cancer Research Center in Heidelberg, Germany. He has worked as a
translational scientist and Principal Investigator in clinical
studies in gastrointestinal oncology for many years. In addition to
being highly published, he has extensive scientific and grant
review experience, and he has received multiple awards and
distinctions.
Dr. L�hr is a licensed physician and board-certified internist
and gastroenterologist. He has a subspeciality in GI Oncology. He
is also a Fellow of the European Board of Gastroenterology (FEBG)
and a Fellow of the American Gastroenterology Association
(AGAF).
Dr. L�hr served as the Principal Investigator for the Phase 1/2
and Phase 2 clinical trials of PharmaCyte’s pancreatic cancer
treatment that were completed in the early 2000s. Not only is he
familiar with the Cell-in-a-Box® live-cell encapsulation technology
that forms the core of PharmaCyte’s pancreatic cancer treatment,
but he has also administered PharmaCyte’s treatment (the
combination of Cell-in-a-Box® capsules with low doses of the
anticancer drug ifosfamide) in clinical trials in patients with
advanced, inoperable pancreatic cancer.
Dr. L�hr has also served as a consultant to PharmaCyte in
connection with its development of treatments for pancreatic cancer
and diabetes using the Cell-in-a-Box® technology. He has expertise
in the treatment of both diseases, in addition to thoroughly
understanding PharmaCyte’s technology and its use in a clinical
setting.
In 2000, Dr. L�hr was appointed Professor of Molecular
Gastroenterology at the University of Heidelberg and became Head of
the same-named Division at the German Cancer Research Center, which
he led until 2010. In 2007, he was appointed full professor of
Gastroenterology and Hepatology at Karolinska Institute. In 2017,
he received the Golden Link Award from the United European
Gastroenterology (UEG) to conduct the first evidence-based European
guidelines for chronic pancreatitis and was in charge of the UEG
guidelines for IgG4-related diseases.
Dr. L�hr has authored more than 340 original peer-reviewed
scientific papers and more than 50 reviews. He has published in all
major journals, including Nature, The Lancet, Gastroenterology, and
GUT. In addition, he has delivered more than 300 invited lectures
at international congresses. He is the author of six books and 40
book chapters. Dr. L�hr has been granted six patents (in Germany
and internationally). He is an Editorial Board Member of the
Journal of Clinical Medicine, Pancreatology, Scientific Reports,
and the World Journal of Gastroenterology.
Dr. L�hr holds a BA in Anthropology & Theology from the
University of Kiel in Kiel, Germany, and MD and PhD degrees from
the Universities of Hamburg and Rostock. Following receipt of his
medical degree, he served a residency in pathology in Hamburg,
Germany, and residencies in internal medicine and gastroenterology
in Erlangen and Rostock, Germany, where he became chief resident
and later attending physician and assistant professor at the
University of Rostock. Dr. L�hr has also completed a postdoctoral
fellowship at the Scripps Clinic & Research Foundation in La
Jolla, California.
About PharmaCyte Biotech
PharmaCyte Biotech, Inc. is a biotechnology company developing
cellular therapies for cancer and diabetes based upon a proprietary
cellulose-based live cell encapsulation technology known as
“Cell-in-a-Box®.” This technology is being used as a platform upon
which therapies for several types of cancer and diabetes are being
developed.
PharmaCyte’s therapy for cancer involves encapsulating
genetically engineered human cells that convert an inactive
chemotherapy drug into its active or “cancer-killing” form. For
pancreatic cancer, these encapsulated cells are implanted in the
blood supply to the patient’s tumor as close as possible to the
site of the tumor. Once implanted, a chemotherapy drug that is
normally activated in the liver (ifosfamide) is given intravenously
at one-third the normal dose. The ifosfamide is carried by the
circulatory system to where the encapsulated cells have been
implanted. When the ifosfamide flows through pores in the capsules,
the live cells inside function as a “bio-artificial liver” and
activate the chemotherapy drug at the site of the cancer. This
“targeted chemotherapy” has proven effective and safe to use in
past clinical trials and we believe results in little to no
treatment related side effects.
PharmaCyte’s therapy for Type 1 diabetes and insulin-dependent
Type 2 diabetes involves encapsulating a human cell line that has
been genetically engineered to produce and release insulin in
response to the levels of blood sugar in the human body. The
encapsulation of the cell line will be done using the
Cell-in-a-Box® technology. Once the encapsulated cells are
implanted in a diabetic patient, we anticipate that they will
function as a “bio-artificial pancreas” for purposes of insulin
production.
Safe Harbor
This press release may contain forward-looking statements within
the meaning of the Private Securities Litigation Reform Act of 1995
that express the current beliefs and expectations of the management
of PharmaCyte. Any statements contained herein that do not describe
historical facts are forward-looking statements that are subject to
risks and uncertainties that could cause actual results,
performance, and achievements to differ materially from those
discussed in such forward-looking statements. Factors that could
affect our actual results include our ability to raise the
necessary capital to fund our operations and to find partners to
supplement our capabilities and resources, our ability to
satisfactorily address the issues raised by the FDA in order to
have the clinical hold on our IND removed, as well as such other
factors that are included in the periodic reports on Form 10-K and
Form 10-Q that we file with the U.S. Securities and Exchange
Commission. These forward- looking statements are made only as of
the date hereof, and we undertake no obligation to update or revise
the forward-looking statements, except as otherwise required by
law, whether as a result of new information, future events or
otherwise.
More information about PharmaCyte Biotech can be found at
www.PharmaCyte.com. Information may also be obtained by contacting
PharmaCyte’s Investor Relations Department.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20220405005475/en/
Investor Relations: Dr. Gerald W. Crabtree PharmaCyte
Biotech, Inc. Telephone: 917.595.2856 Email:
InvestorRelations@PharmaCyte.com
PharmaCyte Biotech (NASDAQ:PMCB)
Historical Stock Chart
From Mar 2024 to Apr 2024
PharmaCyte Biotech (NASDAQ:PMCB)
Historical Stock Chart
From Apr 2023 to Apr 2024